SanofiPrefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Period | Dupixent (€m) | Pharma launches (€m) | Vaccines (€m) | Beyfortus (€m) |
|---|---|---|---|---|
| Q1 2025 | 3,480 | 847 | 1,326 | 284 |
| Q2 2025 | 3,832 | 897 | 1,214 | 72 |
| Q3 2025 | 4,156 | 1,046 | 3,357 | 739 |
| Q4 2025 | 4,246 | 1,121 | 2,039 | 686 |
| Q1 2026 | 4,170 | 1,171 | 1,293 | 284 |
| Q2 2026 | 5,154 | 1,305 | 1,150 | 108 |
Sanofi-Synthélabo and Aventis merge to form Sanofi-Aventis (later Sanofi). Vaccines sit in Sanofi Pasteur, the Pasteur Mérieux Connaught lineage.
FDA approves Beyfortus (nirsevimab) with AstraZeneca for infants. Infant RSV prevention becomes a monoclonal antibody market.
Sanofi agrees to buy Dynavax for about $2.2B (HEPLISAV-B). Close still needs an 8-K. FY 2025 vaccines €7.936B, Beyfortus €1.781B.
FY 2025 call: 2026 vaccine sales guided slightly negative on US weakness. Beyfortus called out as not hit by the childhood-schedule edit.